Glaucoma, Aravind Eye Hospital, Madurai, Tamil Nadu, India
Ophthalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, USA.
Br J Ophthalmol. 2021 Apr;105(4):521-525. doi: 10.1136/bjophthalmol-2019-315558. Epub 2020 Jun 17.
To determine the outcomes of Aurolab aqueous drainage implant (AADI) placed in the superotemporal versus the inferonasal quadrant in adult eyes with refractory glaucoma.
This was a retrospective study of eyes that had AADI placement and completed a minimum of 2-year follow-up. The choice of the quadrant was at the surgeon's discretion and mainly depended on the amount of scarring and conjunctival mobility. The cumulative failure rate of the AADI was defined as intraocular pressure (IOP) >21 mm Hg or not reduced by 20% below baseline on two consecutive follow-up visits after 3 months, IOP ≤5 mm Hg on two consecutive follow-up visits after 3 months, reoperation for glaucoma or a complication, or loss of light perception vision.
We included 84 eyes with AADI in the inferonasal quadrant versus 69 eyes in the superotemporal quadrant. A significant drop in IOP was seen in both groups (18.4±10.4 mm Hg in the inferonasal group vs 17.7±11.1 mm Hg in the superotemporal group; p=0.63) at 3-month follow-up and this was maintained until last follow-up. Best-corrected visual acuity, IOP, number of IOP-lowering medications and complications were similar between the two groups at all time points. The cumulative success rate at 2-year follow-up without IOP-lowering medications was 57.1% (47.1%-68.1%) in the inferonasal group and 50.7% (39.8%-63.1%) in the superotemporal group (p=0.47).
Inferonasal AADI placement appears to be an equally safe and effective surgical option compared with superotemporal AADI placement and may be helpful in certain clinical situations.
确定在难治性青光眼成人眼中,将 Aurolab 水引流植入物(AADI)放置在上象限与下象限的结果。
这是一项回顾性研究,纳入了接受 AADI 植入并完成至少 2 年随访的患者。象限的选择由外科医生决定,主要取决于瘢痕和结膜活动度。AADI 的累积失败率定义为:术后 3 个月内连续两次随访时眼压(IOP)>21mmHg 或未较基线降低 20%;术后 3 个月内连续两次随访时 IOP≤5mmHg;因青光眼或并发症再次手术;或视力丧失。
我们纳入了 84 只在下象限接受 AADI 植入的眼和 69 只在上象限接受 AADI 植入的眼。两组患者的 IOP 均显著下降(下象限组 18.4±10.4mmHg,上象限组 17.7±11.1mmHg;p=0.63),在术后 3 个月时观察到,且一直维持至末次随访。两组患者在所有时间点的最佳矫正视力、IOP、降眼压药物数量和并发症均无显著差异。术后 2 年时不使用降眼压药物的累积成功率,下象限组为 57.1%(47.1%-68.1%),上象限组为 50.7%(39.8%-63.1%)(p=0.47)。
与上象限 AADI 植入相比,下象限 AADI 植入似乎是一种同样安全有效的手术选择,在某些临床情况下可能会有所帮助。